最近の記事

2024/11/07
２１世紀におけるゼブラフィッシュ創薬のグローバル展開
2024/10/25
AIDXゼブラフィッシュ創薬のグローバル展開
2024/10/15
三重大学大学院システムズ薬理学の展開
2024/10/05
システムズ薬理学大学院大募集中です。
2024/09/10
Zebrafish-Based Oncocardionephrology
2024/07/01
ゼブラフィシュによる患者がん移植モデルの個別化医療戦略
2024/07/01
personalized cancer treatment using patient-derived xenografts zebrafish model
2024/06/20
世界最強のハイスループット個別化 in vivo 蛋白尿スクリーニングシステム
2024/06/10
紅麹菌によるゼブラフィッシュ蛋白尿
2024/06/06
DXAIゼブラフィッシュ創薬の新しい展開

一覧に戻る

2023/04/28
  • CiteULike
  • reddit
  • StumbleUpon
  • linkedin
  • Delicious
  • Mendeley
  • はてなブックマーク
  • Youtube
  • Google+
  • Twitter
  • Facebook

oncocardiology of sorafenib

Oncocardiology is a subspecialty of cardiology that focuses on the prevention, diagnosis and treatment of cardiovascular complications caused by cancer therapies. Sorafenib is a tyrosine kinase inhibitor that is used to treat advanced hepatocellular carcinoma and renal cell carcinoma. However, sorafenib can also induce cardiotoxicity, such as hypertension, left ventricular dysfunction, heart failure and ischemia. The characterization of oncocardiology of sorafenib involves the identification of risk factors, biomarkers and imaging modalities that can help to monitor and manage the cardiac effects of this drug. Additionally, the characterization of oncocardiology of sorafenib requires the development of strategies to prevent or mitigate cardiotoxicity, such as dose adjustment, drug interruption or discontinuation, and the use of cardioprotective agents.

関連リンク